Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/Ib First-in-Human Study of EOS100850 (Inupadenant) As a Single Agent and in Combination with Pembrolizumab And/or Chemotherapy in Participants with Advanced Cancers

Next Previous
X
Search
Trial Profile

Phase I/Ib First-in-Human Study of EOS100850 (Inupadenant) As a Single Agent and in Combination with Pembrolizumab And/or Chemotherapy in Participants with Advanced Cancers

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inupadenant (Primary) ; Pembrolizumab (Primary) ; Antineoplastics
  • Indications Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors iTeos Therapeutics

    • Most Recent Events

    • 19 Sep 2024 Status changed from active, no longer recruiting to completed.
    • 26 Apr 2023 Planned End Date changed from 31 Dec 2022 to 1 Jul 2024.
    • 26 Apr 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top